collaborations

GSK consolidates DT and TT vaccine production in Hungary plant, adding 100 jobs With GlaxoSmithKline’s vaccines sales expanding, it figures it needs expanded production as well and some of that will happen at a 10-year-old plant in Hungary as well as Germany. GlaxoSmithKline said on Monday that it would invest £40 m...

PMV Pharma Raises $74M, Aiming to Hit Cancer’s Hard Target- P53 PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The company raised a $74 million Series B round from Topspin Biotech Fun...

ALCMI, ALCF and Scancell partner to evaluate SCIB2 cancer vaccine for NSCLC The Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J. Addario Lung Cancer Foundation (ALCF) have collaborated with UK-based Scancell to assess SCIB2 cancer vaccine to treat patients with non-small-cell lung cancer (NSCLC). SCIB...

Payers block Kaléo's expensive EpiPen challenger Kaléo reintroduced its Auvi-Q last week at a list price of $4,500 for a two-pack in an effort to capture some market share from Mylan’s EpiPen, which is listed at about $600 for a two-pack. Auvi-Q is set to launch next month. Under Kaléo’s pricing strategy, Auvi-Q wil...

Sun Pharma & ICGEB announce exclusive collaboration to develop novel dengue vaccine International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma Ltd. announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause ...

Immune checkpoint activators are small molecules responsible for maintenance, modulation and regulation of immune responses. Its significance in Immuno therapeutics is backed by its functionality to activate the immune checkpoint proteins that are down regulated by tumors, leading to the activation of the immune sys...

The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020. DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Antico...

Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa. DelveInsight Atrial Fibrillation-Market Insights & Drugs ...

Venous Thromboembolism- Market Insights & Drugs Sales Forecast (VTE) -2020: New Report by DelveInsight suggests that the Global VTE market was $4.2 billion in 2015 and expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%. DelveInsight Report “Venous Thromboembolism-Market ...

DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products. Del...